TORONTO, March 12, 2019 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB:
KHRNF), (Frankfurt: A2JMZC), a
vertically integrated cannabis leader with core operations in
Latin America, announced today
that the Company will be presenting at the second annual LD Micro
Virtual Conference on March
13th at 12:20pm
EDT.
Khiron president Chris Naprawa
will present and answer questions from participating investors. The
live presentation can be accessed at the following link:
https://bit.ly/2SY6G0U
To register for the event and receive updates, click here.
The conference will be held via webcast and will feature over 40
companies in the small / micro-cap space.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an
independent resource in the microcap space. What started out as a
newsletter highlighting unique companies has transformed into an
event platform hosting several influential conferences annually
(Invitational, Summit, and Main Event).
In 2015, LDM launched the first pure microcap index (the LDMi)
to exclusively provide intraday information on the entire sector.
LD will continue to provide valuable tools for the benefit of
everyone in the small and microcap universe.
For those interested in attending, please contact David Scher at david@ldmicro.com or
visit www.ldmicro.com for more information.
About Khiron
Khiron Life Sciences Corp. is positioned to be the
dominant integrated cannabis company in Latin America. Khiron has core operations in
Colombia and is fully licensed in
the country for the cultivation, production, domestic distribution,
and international export of both THC (tetrahydrocannabinol) and CBD
(cannabidiol) medical cannabis. In May
2018, Khiron listed on the TSX Venture Exchange, becoming
one of the first Colombian based medical cannabis companies to
trade on any exchange globally.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. Khiron is led by Co-founder and
Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Further information on Khiron can be found
at https://investors.khiron.ca/
Cautionary Notes
Market and Industry Data
This press release contains market and industry data and
forecasts that were obtained from third-party sources, industry
publications and publicly available information. Third-party
sources generally state that the information contained therein has
been obtained from sources believed to be reliable, but there can
be no assurance as to the accuracy or completeness of included
information. Although management believes it to be reliable, the
Company has not independently verified any of the data from
third-party sources referred to in this press release, or analyzed
or verified the underlying studies or surveys relied upon or
referred to by such sources, or ascertained the underlying economic
assumptions relied upon by such sources.
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable Canadian securities legislation. All information
contained herein that is not historical in nature may constitute
forward-looking information. Forward-looking statements may be
identified by statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects",
"continue", "estimate", "forecasts" and other similar expressions.
Forward-looking statements herein include, but are not limited to,
statements regarding the final acceptance of the TSXV and the
commencement of sales in Mexico.
Readers are cautioned to not place undue reliance on
forward-looking information. Actual results and developments may
differ materially from those contemplated by these statements.
Khiron undertakes no obligation to comment analyses, expectations
or statements made by third-parties in respect of Khiron, its
securities, or financial or operating results (as applicable).
Although Khiron believes that the expectations reflected in
forward-looking statements in this press release are reasonable,
such forward-looking statement has been based on expectations,
factors and assumptions concerning future events which may prove to
be inaccurate and are subject to numerous risks and uncertainties,
certain of which are beyond Khiron's control, including the risk
factors discussed in Khiron's Annual Information Form which is
available on Khiron's SEDAR profile at www.sedar.com. The
forward-looking information contained in this press release is
expressly qualified by this cautionary statement and are made as of
the date hereof. Khiron disclaims any intention and has no
obligation or responsibility, except as required by law, to update
or revise any forward-looking information, whether as a result of
new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
SOURCE Khiron Life Sciences Corp.